α-Amylase Ligand 1
α-Amylase Ligand 1 is a human pancreatic α-amylase binder with a Kd of 53.55 μM. α-Amylase Ligand 1 binds within the catalytic site through hydrogen bonding and hydrophobic interactions with active site residues. α-Amylase Ligand 1 is predicted to be orally active with a good safety profile. α-Amylase Ligand 1 can be used for diabetes-related research.
For research use only. We do not sell to patients.
- CAS No.: 77491-07-7
- Formula: C14H11Cl2NO
- Molecular Weight:280.15
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 3T3-L1 | IC50 |
375.34 μg/mL
|
Cytotoxicity against mouse 3T3-L1 preadipocytes assessed as reduction in cell viability after 24 hrs of compound exposure by MTT assay.
Cytotoxicity against mouse 3T3-L1 preadipocytes assessed as reduction in cell viability after 24 hrs of compound exposure by MTT assay.
|
42543020 |
In Vitro
α-Amylase Ligand 1 (compound (I)) (30 min) binds to α-amylase with a dissociation constant (Kd) of 53.55 μM[1].
α-Amylase Ligand 1 (25-250 μg/mL; 24 h) exhibits low cytotoxicity against 3T3-L1 cells with an IC50 of 375.34 μg/mL[1].
The predicted ADME/toxicity profile of α-Amylase Ligand 1 indicates oral absorption potential, possible BBB penetration, non-mutagenicity, and non-hepatotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:3T3-L1 mouse adipocyte cell line
-
Concentration:25, 50, 75, 100, 125, 150, 175, 200, 225 and 250 μg/mL
-
Incubation Time:24 h
-
Result:Reduced cell viability in a dose-dependent manner.
Achieved 76.02% cell viability at 250 μg/mL.
Showed an IC50 of 375.34 μg/mL.
Chemical Information
-
CAS No. 77491-07-7
-
Molecular Weight 280.15
-
Formula C14H11Cl2NO
-
SMILES
OC1=CC=C(C)C=C1/N=C/C2=CC=C(Cl)C=C2Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)